Fairmount Funds Management LLC lifted its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) by 21.1% during the 1st quarter, HoldingsChannel reports. The fund owned 469,264 shares of the biotechnology company's stock after purchasing an additional 81,864 shares during the period. Enanta Pharmaceuticals accounts for 7.9% of Fairmount Funds Management LLC's portfolio, making the stock its 5th biggest position. Fairmount Funds Management LLC's holdings in Enanta Pharmaceuticals were worth $33,402,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also modified their holdings of ENTA. Signaturefd LLC increased its holdings in shares of Enanta Pharmaceuticals by 86.7% during the 1st quarter. Signaturefd LLC now owns 392 shares of the biotechnology company's stock worth $28,000 after buying an additional 182 shares during the last quarter. Captrust Financial Advisors increased its stake in shares of Enanta Pharmaceuticals by 343.8% during the first quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company's stock worth $61,000 after acquiring an additional 660 shares during the period. C M Bidwell & Associates Ltd. acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth about $85,000. KBC Group NV acquired a new position in shares of Enanta Pharmaceuticals during the first quarter worth about $113,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth about $114,000. 97.09% of the stock is owned by hedge funds and other institutional investors.
Get
Enanta Pharmaceuticals alerts:
Enanta Pharmaceuticals Price Performance
Shares of NASDAQ ENTA traded down $0.98 on Monday, hitting $63.06. The company's stock had a trading volume of 5,707 shares, compared to its average volume of 239,682. Enanta Pharmaceuticals, Inc. has a 12-month low of $37.59 and a 12-month high of $102.00. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -10.73 and a beta of 0.55. The stock has a 50 day moving average of $59.75 and a 200-day moving average of $58.66.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last announced its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.17). Enanta Pharmaceuticals had a negative net
margin of 134.21% and a negative return on equity of 32.42%. The business had revenue of $19.48 million during the quarter, compared to analysts' expectations of $20.73 million. During the same period last year, the company earned ($1.19) EPS. The firm's revenue for the quarter was down 9.9% on a year-over-year basis. Sell-side analysts expect that Enanta Pharmaceuticals, Inc. will post -5.75 EPS for the current fiscal year.
Analyst Ratings Changes
A number of brokerages have recently issued reports on ENTA. SVB Leerink boosted their price target on shares of Enanta Pharmaceuticals from $44.00 to $50.00 and gave the stock a "market perform" rating in a research note on Monday, August 1st. Royal Bank of Canada decreased their price objective on shares of Enanta Pharmaceuticals from $67.00 to $66.00 and set a "sector perform" rating on the stock in a report on Tuesday, August 9th. Evercore ISI raised shares of Enanta Pharmaceuticals from an "in-line" rating to an "outperform" rating and set a $62.00 price objective on the stock in a report on Wednesday, July 6th. Oppenheimer boosted their price objective on shares of Enanta Pharmaceuticals from $53.00 to $59.00 and gave the stock a "market perform" rating in a report on Wednesday, August 10th. Finally, Robert W. Baird decreased their price objective on shares of Enanta Pharmaceuticals from $130.00 to $90.00 and set an "outperform" rating on the stock in a report on Thursday, May 19th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Enanta Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $78.63.
Enanta Pharmaceuticals Profile
(Get Rating)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
Featured Stories
- Get a free copy of the StockNews.com research report on Enanta Pharmaceuticals (ENTA)
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 3 Biotech Stocks Gaining Momentum
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
